186 related articles for article (PubMed ID: 38533646)
1. Novel bispecific nanobody mitigates experimental intestinal inflammation in mice by targeting TNF-α and IL-23p19 bioactivities.
Wang J; Kang G; Lu H; de Marco A; Yuan H; Feng Z; Gao M; Wang X; Wang H; Zhang X; Wang Y; Zhang M; Wang P; Feng Y; Liu Z; Cao X; Huang H
Clin Transl Med; 2024 Mar; 14(3):e1636. PubMed ID: 38533646
[TBL] [Abstract][Full Text] [Related]
2. Bispecific soluble cytokine receptor-nanobody fusions inhibit Interleukin (IL-)6 trans-signaling and IL-12/23 or tumor necrosis factor (TNF) signaling.
Gesiorowski A; Ettich J; Werner J; Wittich C; Pieper S; Padrini G; Behnke K; Floss DM; Lang PA; Moll JM; Scheller J
J Biol Chem; 2023 Nov; 299(11):105343. PubMed ID: 37838173
[TBL] [Abstract][Full Text] [Related]
3. Role of the protein annexin A1 on the efficacy of anti-TNF treatment in a murine model of acute colitis.
de Paula-Silva M; Barrios BE; Macció-Maretto L; Sena AA; Farsky SH; Correa SG; Oliani SM
Biochem Pharmacol; 2016 Sep; 115():104-13. PubMed ID: 27343762
[TBL] [Abstract][Full Text] [Related]
4. Inhibitor of apoptosis-stimulating p53 protein protects against inflammatory bowel disease in mice models by inhibiting the nuclear factor kappa B signaling.
Qian K; Yuan L; Wang S; Kuang Y; Jin Q; Long D; Jiang Y; Zhao H; Liu K; Yao H
Clin Exp Immunol; 2021 Aug; 205(2):246-256. PubMed ID: 33942299
[TBL] [Abstract][Full Text] [Related]
5. ETS-1 facilitates Th1 cell-mediated mucosal inflammation in inflammatory bowel diseases through upregulating CIRBP.
He Q; Gao H; Chang YL; Wu X; Lin R; Li G; Lin J; Lu H; Chen H; Li Z; Cong Y; Yao J; Liu Z
J Autoimmun; 2022 Oct; 132():102872. PubMed ID: 35926374
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of thalidomide on trinitrobenzene sulfonate-induced colitis in young rats and its mechanism.
Xu J; Zheng C; Huang Y; Liang Y
Chin Med J (Engl); 2014; 127(12):2368-75. PubMed ID: 24931258
[TBL] [Abstract][Full Text] [Related]
7. miR-301a promotes intestinal mucosal inflammation through induction of IL-17A and TNF-α in IBD.
He C; Shi Y; Wu R; Sun M; Fang L; Wu W; Liu C; Tang M; Li Z; Wang P; Cong Y; Liu Z
Gut; 2016 Dec; 65(12):1938-1950. PubMed ID: 26338824
[TBL] [Abstract][Full Text] [Related]
8. Benzenediamine analog FC-99 inhibits TLR2 and TLR4 signaling in peritoneal macrophage in vitro.
Yang L; Dou H; Song Y; Hou Y
Life Sci; 2016 Jan; 144():129-37. PubMed ID: 26620764
[TBL] [Abstract][Full Text] [Related]
9. Preparation of Herbal Formulation for Inflammatory Bowel Disease Based on In Vitro Screening and In Vivo Evaluation in a Mouse Model of Experimental Colitis.
Lee J; Choi HS; Lee J; Park J; Kim SB; Shin MS; Lee S; Hwang GS; Koo BA; Kang KS
Molecules; 2019 Jan; 24(3):. PubMed ID: 30696085
[TBL] [Abstract][Full Text] [Related]
10. Blockage of tumor necrosis factor prevents intestinal mucosal inflammation through down-regulation of interleukin-23 secretion.
Liu Z; Jiu J; Liu S; Fa X; Li F; Du Y
J Autoimmun; 2007; 29(2-3):187-94. PubMed ID: 17804196
[TBL] [Abstract][Full Text] [Related]
11. A novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates inflammatory colonic injury in mice.
Funakoshi T; Yamashita K; Ichikawa N; Fukai M; Suzuki T; Goto R; Oura T; Kobayashi N; Katsurada T; Ichihara S; Ozaki M; Umezawa K; Todo S
J Crohns Colitis; 2012 Mar; 6(2):215-25. PubMed ID: 22325176
[TBL] [Abstract][Full Text] [Related]
12. Fc Receptor-mediated Effector Function Contributes to the Therapeutic Response of Anti-TNF Monoclonal Antibodies in a Mouse Model of Inflammatory Bowel Disease.
McRae BL; Levin AD; Wildenberg ME; Koelink PJ; Bousquet P; Mikaelian I; Sterman AS; Bryant S; D'Haens G; Kamath R; Salfeld J; van den Brink GR
J Crohns Colitis; 2016 Jan; 10(1):69-76. PubMed ID: 26429698
[TBL] [Abstract][Full Text] [Related]
13. Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action.
Yousef M; Pichyangkura R; Soodvilai S; Chatsudthipong V; Muanprasat C
Pharmacol Res; 2012 Jul; 66(1):66-79. PubMed ID: 22475725
[TBL] [Abstract][Full Text] [Related]
14. PPARGC1A affects inflammatory responses in photodynamic therapy (PDT)-treated inflammatory bowel disease (IBD).
Liu C; Jiang Y; Liu G; Guo Z; Jin Q; Long D; Zhou W; Qian K; Zhao H; Liu K
Biochem Pharmacol; 2022 Aug; 202():115119. PubMed ID: 35667414
[TBL] [Abstract][Full Text] [Related]
15. Heat-Killed
Feng C; Zhang W; Zhang T; He Q; Kwok LY; Tan Y; Zhang H
Nutrients; 2022 Dec; 14(24):. PubMed ID: 36558391
[TBL] [Abstract][Full Text] [Related]
16. Effect of COX-2 inhibitor lumiracoxib and the TNF-α antagonist etanercept on TNBS-induced colitis in Wistar rats.
Paiotti AP; Ribeiro DA; Silva RM; Marchi P; Oshima CT; Neto RA; Miszputen SJ; Franco M
J Mol Histol; 2012 Jun; 43(3):307-17. PubMed ID: 22426941
[TBL] [Abstract][Full Text] [Related]
17. Effect of exogenous galectin-9, a natural TIM-3 ligand, on the severity of TNBS- and DSS-induced colitis in mice.
Xiong H; Xue G; Zhang Y; Wu S; Zhao Q; Zhao R; Zhou N; Xie Y
Int Immunopharmacol; 2023 Feb; 115():109645. PubMed ID: 36610329
[TBL] [Abstract][Full Text] [Related]
18. Co-administration of Lactobacillus gasseri KBL697 and tumor necrosis factor-alpha inhibitor infliximab improves colitis in mice.
Han DH; Kim WK; Lee C; Park S; Lee K; Jang SJ; Ko G
Sci Rep; 2022 Jun; 12(1):9640. PubMed ID: 35688918
[TBL] [Abstract][Full Text] [Related]
19. The impact of mangiferin from Belamcanda chinensis on experimental colitis in rats.
Szandruk M; Merwid-Ląd A; Szeląg A
Inflammopharmacology; 2018 Apr; 26(2):571-581. PubMed ID: 28337639
[TBL] [Abstract][Full Text] [Related]
20. Efficiency of Orexin-A for Inflammatory Flare and Mucosal Healing in Experimental Colitis: Comparison with the Anti-TNF Alpha Infliximab.
Blais A; Lan A; Blachier F; Benamouzig R; Jouet P; Couvineau A
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
